HOME >> MEDICINE >> NEWS
Vitamin supplementation could slow arteriosclerosis in heart-transplant patients

A US randomised trial in this weeks issue of THE LANCET suggests that vitamin C and E supplementation could be of clinical benefit in delaying the onset of arteriosclerosis in the first year after heart transplantation.

Around 70% of patients develop arteriosclerosis within three years after heart transplantation, which is thought to be associated with oxidant stress. James Fang and colleagues from Brigham and Women's Hospital, Boston, USA, proposed that treatment with antioxidant vitamins C and E would slow the progression of transplant-associated arteriosclerosis.

40 patients (0-2 years after heart transplantation) were randomly assigned vitamin C 500 mg plus vitamin E 400 IU, each twice daily, or placebo, for 1 year. The primary endpoint was the change in average intimal index (plaque area divided by vessel area) measured by intravascular ultrasonography (IVUS). Coronary endothelium-dependent vasoreactivity was assessed with intracoronary acetylcholine infusions. IVUS, coronary vasoreactivity, and vitamin C and E plasma concentrations were assessed at baseline and at 1 year follow-up.

Vitamin C and E concentrations increased in the treatment group, but not in the placebo group, as expected. During 1 year of treatment, the intimal index increased in the placebo group by 8% but did not change significantly in the treatment group. Coronary endothelial function remained stable in both groups.

James Fang comments: Our results suggest that vitamins C and E provide a clinically useful approach to reducing arteriosclerosis after cardiac transplantation. Antioxidant therapy with these vitamins may also be useful in other solid-organ allografts, such as kidney, lung, and liver transplants, in which obliteration of vascular or tubular structures limits long-term success. Further investigations are warranted to investigate whether the beneficial effects of vitamins C and E are sustained over many years when most of the clinical complicat
'"/>

Contact: Richard Lane
richard.lane@lancet.com
44-20-7424-4949
Lancet
28-Mar-2002


Page: 1 2

Related medicine news :

1. Vitamin E may not prevent cancer or cardiovascular events, but may increase risk for heart failure
2. Vitamin C reduces level of C-reactive protein, finds UC Berkeley-led study
3. Vitamins good for some older women/bad for others
4. Vitamin B-12 levels linked to bone loss in aging women
5. Vitamin supplement use may reduce effects of Alzheimers disease
6. Vitamins help treat depression
7. Vitamin D deficiency emerges as new epidemic
8. Vitamins C and E improve cardiovascular health in children with high cholesterol, study says
9. Vitamins C and E may enhance effectiveness of insulin for diabetes
10. Vitamins valuable for baby boomers eye disease
11. Vitamin E fails to join heart-health regimen

Post Your Comments:
(Date:5/18/2013)... In a May 14, 2013 article entitled “Angelina Jolie ... Gene,” Fox News reported the movie star had opted ... a gene that doctors estimated gave her an 87 ... risk of ovarian cancer (go to: goo.gl/5JHBP). Ms. Jolie’s ... a blog post entitled “A Patient’s Journey: Angelina Jolie” ...
(Date:5/18/2013)... Coral Springs, FL (PRWEB) May 18, 2013 ... segment dedicated to the special places we call home. These ... found on maps. They are the locations where the people ... The first-rate show takes viewers off the highways and shares ... the best of both nations with an American sports and ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 Family Magazine of ... for excellence by Follow Media Consulting, Inc. in the category ... the continued commitment and dedication of the areas best in ... No one knows parenting better than Brenda Hyde, a mother ... to help parents know about the vast resources available to ...
(Date:5/18/2013)... 2013 The “Sleep Apnea Diagnostic & ... Masks, Adaptive Servo-Ventilation (ASV), Oral Appliances, Nasal EPAP, Neurostimulation] ... analyzes and studies the major market drivers, restraints, and ... the World. , Browse , ... Figures , 318 pagesand in-depth TOC ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 The California ... 2013 therapies. At the Ayurvedic Spa , the ... panchakarma practitioner and lifestyle recommendations and stress ... “knowledge of life", is the traditional healthcare system of ... life of harmony is the basis for all optimum ...
Breaking Medicine News(10 mins):Health News:Angelina Jolie – Scarless Breast Augmentation Surgery 2Health News:Communities of Distinction TV Presents "A Place to Call Home" Segment 2Health News:Summer Camps in DC "Best of the Best" Awarded to Family Magazine of Washington DC for Excellence by Follow Media Consulting, Inc. 2Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 2Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 3Health News:Ayurveda Spa Treatments Now Offered at the California College of Ayurveda Panchakarma Center 2
(Date:5/17/2013)... Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) ... systems, announced today that the United States Food and ... Drug application(IND) for ORMD-0801, its oral insulin capsule. ... clearance to proceed," stated Nadav Kidron ... major milestone for Oramed and we look forward to ...
(Date:5/16/2013)... May 16, 2013  PTC Therapeutics, Inc., today announced ... S-1 with the U.S. Securities and Exchange Commission ("SEC") ... common stock. The number of shares to be offered ... been determined. (Logo:  http://photos.prnewswire.com/prnh/20010919/PTCLOGO ) ... as joint book-running managers for the offering. Cowen and ...
(Date:5/16/2013)... Calif. , May 16, 2013  Amgen (NASDAQ: ... Sciences Conference on Tuesday, May 21, 2013, at the Sheraton ... , beginning at 10:00 a.m. Eastern Daylight Time. ... president of Research and Development at Amgen, will present at ... from the Events Calendar on Amgen,s website, www.amgen.com , ...
Breaking Medicine Technology:Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 2Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 3PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering 2
Cached News: